Aerovate Therapeutics Inc (AVTE) Event May 16, 2022, 00:00 UTC (76% Positive) AEROVATE THERAPEUTICS, INC. (AVTE) Reports 75% Loss Reduction for 2022-03-31 Full text
Register to leave comments News bot Oct. 29, 2025, 9:02 a.m. 🏢 Aerovate Therapeutics Inc (AVTE) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-05-16 📊 Period of Report: 2022-03-31 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-2.78M $-10.91M $8.13M +74.51% 📉 Total Assets $175.36M $167.00M $8.36M +5.01% 📈 Total Liabilities $2.94M $5.05M $-2.11M -41.71% 📈 Stockholders' Equity $-16.11M $-16.20M $86.00K +0.53% ↗️ Operating Income/Loss $-2.78M $-11.02M $8.24M +74.77% 📉 R&D Expense $2.20M $7.25M $-5.06M -69.73% 📈 Earningspersharebasic $-11.49 $-0.45 $-11.04 -2453.33% 📉 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Aerovate Therapeutics Inc (AVTE) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document